Agenus Inc.a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.

   For further information about this manuscript, please visit http://neuro-oncology.oxfordjournals.org.